ERBB2 and carcinoma: Invasive ductal carcinoma cell line BT474 is known to overexpress HER2 receptors (~2.75 × 106 HER2 molecules per cell [55] vs., e.g., ~4 × 104 for A431 cells) and is sensitive to specific HER2-blocking therapeutic antibody trastuzumab [40].